PHI and Germany’s federal institute for materials research pursue joint patent application
Phase Holographic Imaging (PHI) and Germany’s federal institute for materials research (BAM) has agreed to jointly enter the national phase of international patent application “Molecularly Imprinted Polymers” in Europe, USA, China and Japan. An international patent application is a preliminary review prior to national applications. Patents are only granted nationally.
PHI has obtained a 75 % ownership of the invention by compensating three of the inventors for accrued expenses. In the event of successful commercialization, the inventors will be further compensated by PHI according to the Swedish Act on Rights to Inventions made by Employees. BAM retains its 25 % ownership of the invention.
Scientists have extensively searched for a biomarker which at an early stage uniquely identifies cancer, without success. However, new research show that a combination of biomarkers are uniquely present in cancer cells. The invention relates to the nanoparticles which are used and developed in the GlycoImaging project to identify these biomarkers. GlycoImaging is a EU funded collaboration between PHI, BAM, Malmö University, University of Copenhagen, University of Turku and Umeå University, aiming to develop improved cancer diagnostic applications based on PHI’s holographic microscopy technology and molecularly imprinted nanoparticles, also known as synthetic plastic antibodies.
The Bundesanstalt für Materialforschung und -prüfung (BAM) is a non-commercial senior scientific and technical federal institute with responsibility to Germany’s Federal Ministry for Economic Affairs and Energy. The particular remit of BAM is to advance safety in technology and chemistry, to test materials and systems (thereby analyzing the test results based on the applied principles of physics and chemistry and providing reference methods and reference materials), to promote the transfer of knowledge and technology in its key fields of research, to collaborate on the development of statutory regulations (e.g. safety standards and threshold limits) and to advise the German government, industry, national and international organizations on materials science and chemistry.
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 20, 2017.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.